Riley
Forum Replies Created
-
Posts
-
Hi Mary,
I will keep you updated if we make any progress.
My mother in law had a large tumor removed from her liver during July 2016. She had two cisplatin treatments, but then decided not to continue with treatment, as it was palliative and not curative.
Yes, the trial is using very simple methods to evaluate response of the treatment. We are fortunate though to have access to MRIs etc and will make use of it.
Regards,
Jason
Hi Positivity,
V3-X is a therapeutic vaccine (not for prevention bu to treat). The company developing this had very good results on another product they developed (they actually by accident discovered its beneficial effects on liver cancer when treating Hepatitis patients) for liver cancer.
Here is more info on the success they had with liver cancer:
Hi Mary,
Thank you for your reply. Yes, the therapeutic vaccine for HCC is known as Hepko V5. The Study Director for this trial, Dr. Bourinbaiar send us the V3-X as well as Hepkto V5.
It seems that Dr. Bourinbaiar treated some CCA patients and got about a 50% response using the Hepko V5 vaccine. (although theoretically it should not be of much benefit to CCA patients). The same methodology was followed in creating the V3-X vaccine – using heat and chemically inactivated blood from CCA patients.
My mother in law has been using the Hepko V5/V3-X combination for a little under 3 weeks. Her White Blood Count has come down from 18 000 to 7 000. Some inflammation markers also came down. She says that she has less abdominal pain and sleeps better. She does however still feel weak and sleeps a lot.
The V3-X trial uses the reduction in the CA19.9 marker to determine if the tumor burden is decreasing or not. We will do the test probably in a week’s time and if an improvement go for MRIs.
Regards,
Jason
